Stent developer Amaranth Medical is launching the MEND-II clinical trial to test its Fortitude Sirolimus-Eluting Bioresorbable Scaffold, a sign that companies large and small are keenly the new treatment paradigm for coronary artery disease involving stents that disintegrate within the body after a couple of years.
Amid mounting industry pressure to unveil a therapy to counter the deadly Ebola outbreak, researchers are developing an innovative dialysis device that fights the disease by filtering blood.
Over the last few years we've seen some big changes in the way some drugs are developed. What better time to host a new FierceBiotech executive panel discussion on current trends in late-stage development?
Quintiles, the world's largest CRO, is dialing up its focus on nascent drugmakers, launching a biotech-focused service offering designed to meet the particular needs of the industry's seedlings without losing them in the Big Pharma shuffle.
Risk-sharing researcher Evotec took a blow last week when partner Hyperion Therapeutics pulled the plug on a diabetes trial, but the German company is keeping things moving, expanding an agreement that will put it to work on treatments for Huntington's disease.
Nonprofit researcher SRI International has struck a deal with Japanese drugmaker Nobelpharma to collaborate on a new treatment for the painful gynecological disease endometriosis.
Alivira Animal Health, a joint venture between Shasun Pharmaceuticals and SeQuent Scientific, has grabbed a 60% stake in Turkey's Provet Veterinary Products.
Medidata is providing the underlying technology, while Icon is contributing its pre-validated surveys.
Eli Lilly has harbored big hopes for its newly approved cancer fighter Cyramza. It expects it to get a string approvals, and with new data in hand, it said it will go to the FDA with an application for colon cancer in the first half of next year.
Partners Biogen Idec and AbbVie are touting late-stage results for their new, monthly multiple sclerosis treatment, preparing to hand in regulatory applications next year and contend in a crowded market.